Sanofi CEO Paul Hudson advocates for AI in drug development, claiming it can make unbiased decisions without career attachments. Speaking at a Davos panel, he explained that AI helps determine whether drugs should advance in the approval process, providing a fresh perspective free from personal investment. Sanofi has utilized AI in its discovery process for about three years, amidst significant investment in drug development, while emphasizing that AI complements human roles rather than replacing them.
